Maziarz Richard T, Hao Yanni, Guerin Annie, Gauthier Genevieve, Gauthier-Loiselle Marjolaine, Thomas Simu K, Eldjerou Lamis
a Center for Hematologic Malignancies , Knight Cancer Institute Oregon Health & Science University (OHSU) , Portland , OR , USA.
b Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
Leuk Lymphoma. 2018 May;59(5):1133-1142. doi: 10.1080/10428194.2017.1375100. Epub 2017 Sep 21.
This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.
本研究描述了在真实临床环境中，成年弥漫性大B细胞淋巴瘤（DLBCL）患者接受异基因造血干细胞移植（HSCT）后的短期和长期医疗资源利用（HRU）及费用情况。在101例接受异基因HSCT的DLBCL患者中，描述了异基因HSCT后长达三年的HRU和直接医疗费用。HRU和费用相当可观，在HSCT后的第一年观察到最密集的HRU和最高的医疗费用（38个住院日；68个门诊日，平均医疗费用为455,741美元）。尽管HRU和费用随时间下降，但在HSCT后的第三年仍然很高（4个住院日；27个门诊日，平均医疗费用为72,957美元）。总体而言，本研究表明，DLBCL患者接受异基因HSCT后的经济负担很重。
